Single-dose Sputnik Light vaccine authorized in India

Moscow, August 6, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the approval of the Russian single-dose Sputnik Light vaccine against coronavirus by the Drug Controller General of India (DCGI).

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V. The vaccine demonstrates an efficacy level of over 80%, which is higher than that of many foreign two-dose vaccines.

Sputnik Light is based on a proven and well-studied platform of human adenoviral vectors. The data obtained in a number of countries, including Russia, Argentina, Azerbaijan, UAE and others, demonstrates that Sputnik Light has a high safety and efficacy profile.

Clinical studies are now ongoing in a number of countries to combine Sputnik Light with vaccines of other manufacturers. The heterogeneous boosting approach (“vaccine cocktail” using human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component) was at the core of Sputnik V, the world’s first registered vaccine against coronavirus. With this approach proving successful in creating a longer and more durable immunity against the coronavirus, RDIF took the lead in initiating partnerships with other vaccine producers to conduct joint studies of a combination of the first component of Sputnik V with foreign vaccines.

Sputnik Light will add to India’s national vaccine portfolio and join the two-dose Sputnik V Russian vaccine against coronavirus, which was approved in the country in April 2021. India is the leading production hub for Sputnik V. RDIF has reached agreements with the leading pharmaceutical companies in the country (Serum Institute of India, the world’s largest vaccine manufacturer by volume, as well as Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech and Morepen) to produce Sputnik V.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“The Sputnik Light vaccine provides a number of advantages in the fight against coronavirus. A single-dose vaccine can be administered to a large number of people in a short time frame thus creating herd immunity more quickly. Moreover, Sputnik Light can be used as a booster shot in combination with other vaccines, and RDIF is now sponsoring this kind of studies. Thanks to approval by DCGI, vaccine cooperation between Russian and India is now involving the second Russian vaccine and Sputnik Light can surely play an important role in speeding up the vaccination program in the country. ”

Key advantages of Sputnik Light:

  • Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.

  • An efficacy level of almost 80% is higher than that of many two-dose vaccines.

  • Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests.

  • Sputnik Light is compatible with standard vaccine storage and logistics requirements.

  • The Sputnik Light vaccine is based on a well-studied human adenoviral vector platform that has proven to be safe and effective, with no long-term side effects, as confirmed in over 250 clinical trials conducted globally over the past two decades (while the history of use of human adenoviruses in vaccine development started in 1953).


Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 90 projects with foreign partners totaling RUB 2.1 tn. RDIF portfolio companies employ more than 1 million people and generate revenues equivalent to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at

For additional information contact:

Alexey Urazov
Russian Direct Investment Fund
Director for External Communications

Mobile: +7 915 312 76 65
E-mail: [email protected]

Andrew Leach / Maria Shiryaevskaya
Hudson Sandler

Tel: +44 (0) 20 7796 4133

Message has been successfully sent!

Thank you!
You have been subscribed